T-lymphocyte activation antigen CD80 is a B-cell costimulator and podocyte injury marker originally described in lupus nephritis; CD80 blockade with abatacept disappointed in a lupus nephritis trial. A study now suggests abatacept efficacy in focal and segmental glomerulosclerosis. Small patient numbers and concurrent treatment regimens call for more definitive studies regarding this therapeutic strategy.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Increased urinary CD80 excretion and podocyturia in Fabry disease
Journal of Translational Medicine Open Access 13 October 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Maxwell, L. J. & Singh, J. A. Abatacept for rheumatoid arthritis: a Cochrane systematic review. J. Rheumatol. 37, 234–245 (2010).
Yu, C.-C. et al. Abatacept in B7-1-positive proteinuric kidney disease. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1304572.
Vincenti, F. et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am. J. Transplant. 10, 535–546 (2010).
Pestana, J. O. M. et al. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am. J. Transplant. 12, 630–639 (2012).
Wei, C. et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat. Med. 17, 952–960 (2011).
Clement, L. C. et al. Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat. Med. 17, 117–122 (2011).
Reiser, J. et al. Induction of B7–1 in podocytes is associated with nephrotic syndrome. J. Clin. Invest. 113, 1390–1397 (2004).
Ishimoto, T. et al. Toll-like receptor 3 ligand, polyIC, induces proteinuria and glomerular CD80, and increases urinary CD80 in mice. Nephrol. Dial. Transplant. 28, 1439–1446 (2013).
Furie, R. et al. Efficacy and safety of abatacept over 12 months in patients with lupus nephritis: results from a multicenter, randomized, double-blind, placebo controlled phase II/III study [abstract]. Arthritis Rheum. 63 (Suppl. 10), a2469 (2011).
Cravedi, P., Kopp, J. B. & Remuzzi, G. Recent progress in the pathophysiology and treatment of FSGS recurrence. Am. J. Transplant. 13, 266–274 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J. Reiser has pending or issued patents on novel kidney-protective therapies. He stands to gain royalties from their commercialization. N. Alachkar declares no competing interests.
Rights and permissions
About this article
Cite this article
Reiser, J., Alachkar, N. Abate or applaud abatacept in proteinuric kidney disease?. Nat Rev Nephrol 10, 128–130 (2014). https://doi.org/10.1038/nrneph.2013.276
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2013.276
This article is cited by
-
Clinical research progress of novel biologics for the treatment of lupus nephritis
Clinical and Experimental Medicine (2023)
-
Efficacy and safety of novel biologics in the treatment of lupus nephritis based on registered clinical trials: a systematic review and network meta-analysis
Clinical and Experimental Medicine (2023)
-
Losartan Protects Podocytes against High Glucose-induced Injury by Inhibiting B7-1 Expression
Current Medical Science (2021)
-
The role of B7-1 in proteinuria of glomerular origin
Nature Reviews Nephrology (2018)
-
Increased urinary CD80 excretion and podocyturia in Fabry disease
Journal of Translational Medicine (2016)